NDA 022198 · Apotex
Sancuso
Granisetron · Transdermal · Serotonin-3 Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Sep 12, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
124
32 Phase 3, 5 recruiting
FAERS reports
10,458
8,771 serious, 1,879 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2024.
SANCUSO ® is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration. SANCUSO is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. ( 1 )
Mechanism: Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1, 5-HT 1A , 5-HT 1B/C , 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SANCUSO · GRANISETRON 3.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Granisetron" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for CancerPivotal-lookingCompleted
Heron TherapeuticsIndustry
NCT00343460 · 1,428 participants · Start Jun 2006 · Primary completion Sep 2008
Drug: APF530; dexamethasone and 1 more · For: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Sites: Anniston, Alabama; Glendale, Arizona; Tucson, Arizona · 52 sites in all
- Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyPivotal-lookingCompleted
Tesaro, Inc.GSK (GSK)
NCT01500226 · 1,369 participants · Start Feb 2012 · Primary completion Feb 2014
Drug: Rolapitant; Granisetron and 2 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Waltham, Massachusetts
- Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Taiho Pharmaceutical Co., Ltd.Industry
NCT00359567 · 1,140 participants (planned) · Start Jul 2006 · Primary completion May 2007
Drug: palonosetron; granisetron hydrochloride · For: Chemotherapy-Induced Nausea and Vomiting
Sites: 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
- Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialPivotal-lookingCompleted
Joseph RoscoeAcademic, hospital or other
NCT00475085 · 1,021 participants · Start Dec 2006 · Primary completion Dec 2012
Drug: aprepitant; dexamethasone and 4 more · For: Nausea
Sites: Mobile, Alabama; Decatur, Illinois; Wichita, Kansas · 16 sites in all
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECPivotal-lookingCompleted
Heron TherapeuticsIndustry
NCT02106494 · 942 participants · Start Mar 2014 · Primary completion May 2015
Drug: APF530; Ondansetron and 4 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Phoenix, Arizona; Downey, California; Riverside, California · 7 sites in all
- Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by ChemotherapyPivotal-lookingCompleted
Gary MorrowAcademic, hospital or other
NCT00003817 · 700 participants (planned) · Start Oct 1999 · Primary completion Jul 2001
Drug: dolasetron mesylate; granisetron hydrochloride and 2 more · For: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Sites: Hackensack, New Jersey; Rochester, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,337
- vomiting768
- febrile neutropenia741
- diarrhoea728
- pyrexia664
- death611
- dyspnoea605
- fatigue570
- neutropenia492
- anaemia491
- off label use461
- constipation404
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 129 |
| 2005 | 106 |
| 2006 | 60 |
| 2007 | 74 |
| 2008 | 63 |
| 2009 | 54 |
| 2010 | 129 |
| 2011 | 250 |
| 2012 | 626 |
| 2013 | 392 |
| 2014 | 446 |
| 2015 | 481 |
| 2016 | 829 |
| 2017 | 686 |
| 2018 | 859 |
| 2019 | 943 |
| 2020 | 871 |
| 2021 | 834 |
| 2022 | 831 |
| 2023 | 528 |
| 2024 | 461 |
| 2025 | 495 |
| 2026 | 310 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sancuso (Granisetron)
2024 spending
$6.6M
Beneficiaries
1,220
3,171 claims
Per beneficiary
$5,415
$669.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,999,796 |
| 2021 | $7,590,638 |
| 2022 | $7,189,513 |
| 2023 | $6,806,991 |
| 2024 | $6,606,813 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Niño-Serna LF, Acosta-Reyes J, Veroniki AA, et al. · Pediatrics 2020 · Network Meta-Analysis, Systematic Review
- Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis.
Christidis N, Al-Moraissi EA, Barjandi G, et al. · Drugs 2024 · Systematic Review, Network Meta-Analysis
- Transdermal granisetron.
Duggan ST, Curran MP · Drugs 2009 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis.
Weibel S, Schaefer MS, Raj D, et al. · Anaesthesia 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.
Patel P, Robinson PD, Wahib N, et al. · Support Care Cancer 2022 · Meta-Analysis, Systematic Review
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.